Chronic Graft Versus Host Disease Clinical Trial
Official title:
A Phase 2, Open-label, Single-arm, Intra-subject Dose-escalation Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Moderate or Severe Chronic GVHD Inadequately Responding to First or Second Line Therapy
Chronic graft versus host diseasre (GVHD) is a serious reaction that might occur in a person
(the host) who has received cells or organs (graft) from another person because the graft
attacks the host's cells. Currently there are no approved therapies for chronic GVHD in the
USA, and patients with chroninc GVHD are treated with immunosuppressant drugs. T-lymphocytes
(a type of white blood cells) are likely to play a role in the development of chronic GVHD.
Due to the capacity of ponesimod to block the traffic of T-lymphocytes, ponesimod may be a
new therapeutic approach to treat chroninc GVHD.
The main objective of this study is to assess the effectiveness and safety of several doses
of ponesimod in subjects with chronic GVHD who did not respond to standard available
treatments.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT01804686 -
A Long-term Extension Study of PCI-32765 (Ibrutinib)
|
Phase 3 | |
| Terminated |
NCT02337517 -
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
|
Phase 2 | |
| Recruiting |
NCT03839069 -
Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis
|
N/A | |
| Active, not recruiting |
NCT00637689 -
Improving Outcomes Assessment in Chronic GVHD
|
||
| Not yet recruiting |
NCT06233110 -
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
|
Phase 1 | |
| Active, not recruiting |
NCT01937468 -
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
|
Phase 1 | |
| Completed |
NCT01810718 -
Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD
|
Phase 1 | |
| Completed |
NCT01380535 -
Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)
|
Early Phase 1 | |
| Terminated |
NCT01964625 -
Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD)
|
N/A | |
| Active, not recruiting |
NCT03790332 -
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
|
Phase 1/Phase 2 | |
| Completed |
NCT01680965 -
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT02491359 -
Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease
|
Phase 2 | |
| Recruiting |
NCT06300320 -
A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease
|
Phase 2 | |
| Recruiting |
NCT05922761 -
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
|
Phase 2 | |
| Terminated |
NCT02701634 -
Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)
|
Phase 2 | |
| Recruiting |
NCT06247150 -
Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)
|
N/A | |
| Active, not recruiting |
NCT04212416 -
Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease
|
Phase 1 | |
| Completed |
NCT02959944 -
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
|
Phase 3 | |
| Completed |
NCT01954979 -
Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
|
Phase 1 | |
| Active, not recruiting |
NCT04640025 -
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
|
Phase 2 |